Intravenous flecainide acetate for the clinical management of paroxysmal tachycardias
Why the study?
Does intravenous flecainide acetate terminate recurrent paroxysmal tachycardias in patients undergoing electrophysiological evaluation?
Population
40 patients undergoing routine electrophysiological evaluation for the investigation of recurrent paroxysmal…
Design
Case_series
Follow-up
Acute (during electrophysiological evaluation)
Authors
Discussion
Loading...
Member takes
Implication
May guide IV flecainide use in AF/VT but not flutter; leaves open randomized confirmation of rates.
Structured PICO
Does intravenous flecainide acetate terminate recurrent paroxysmal tachycardias in patients undergoing electrophysiological evaluation?
P
Population
40 patients undergoing routine electrophysiological evaluation for the investigation of recurrent paroxysmal tachycardias (10 with recurrent atrial flutter, 11 with recurrent atrial fibrillation, and 19 with recurrent ventricular tachyarrhythmias).
I
Intervention
Intravenous flecainide acetate (2 mg/kg) administered over 5 to 10 minutes.
O
Outcome
Restoration of sinus rhythm (termination of tachycardia)
Intravenous flecainide is highly effective for the acute termination of paroxysmal atrial fibrillation and ventricular tachycardia, but has limited efficacy for atrial flutter.
Cite This Study
Nathan et al. (1987) studied this question.